TDMS Study 96021-01 Pathology Tables
NTP Experiment-Test: 96021-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 10/09/03
Route: GAVAGE TOXIC EQUIVALENCY FACTOR EVALUATION (PCB 153) Time: 10:00:49
FINAL #3
Facility: Battelle Columbus Laboratory
Chemical CAS #: 35065-27-1
Lock Date: 01/16/02
Cage Range: All
Reasons For Removal: 25018 Dosing Accident 25019 Moribund Sacrifice
25020 Natural Death 25021 Terminal Sacrifice
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 1
NTP Experiment-Test: 96021-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 10/09/03
Route: GAVAGE TOXIC EQUIVALENCY FACTOR EVALUATION (PCB 153) Time: 10:00:49
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 UG/KG 10 UG/KG 100 300 1000 3000
UG/KG UG/KG UG/KG UG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 98 86 98 98 98 80
Early Deaths
Natural Death 11 15 8 9 15 11
Moribund Sacrifice 18 23 17 22 18 19
Dosing Accident 1
Survivors
Terminal Sacrifice 24 16 28 20 20 21
Natural Death 1
Animals Examined Microscopically 53 54 53 53 53 51
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (53) (54) (53) (53) (53) (51)
Muscularis, Inflammation 3 [2.0] 1 [2.0] 2 [2.0] 1 [2.0]
Periesophageal Tissue, Hemorrhage 1 [3.0]
Periesophageal Tissue, Inflammation 1 [2.0]
Intestine Large, Colon (53) (54) (53) (53) (53) (50)
Inflammation, Chronic Active 1 [3.0]
Parasite Metazoan 1 1 1 2
Intestine Large, Rectum (53) (54) (53) (53) (53) (50)
Inflammation, Chronic Active 1 [3.0]
Parasite Metazoan 1 2 3 7 5 5
Intestine Large, Cecum (53) (54) (53) (53) (53) (50)
Inflammation, Chronic Active 1 [3.0]
Intestine Small, Duodenum (53) (54) (53) (53) (53) (51)
Parasite Metazoan 1
Intestine Small, Jejunum (53) (54) (53) (53) (53) (50)
Peyer's Patch, Hyperplasia, Lymphoid 1 [2.0] 1 [3.0]
Intestine Small, Ileum (52) (54) (53) (53) (53) (50)
Hyperplasia, Lymphoid 1 [3.0]
Liver (53) (54) (53) (53) (53) (51)
Angiectasis 5 [1.8] 2 [2.5] 2 [1.0] 1 [1.0] 8 [1.9] 4 [1.5]
Basophilic Focus 8 5 16 6 3 8
Basophilic Focus, Multiple 8 12 9 7 7 2
Cholangiofibrosis 1 [2.0]
Clear Cell Focus 3 3 4 2
Clear Cell Focus, Multiple 3 2 1
Eosinophilic Focus 5 1 8 7 14 6
Eosinophilic Focus, Multiple 7 1 8 12 9 12
Fatty Change, Diffuse 3 [1.0] 7 [1.4] 2 [1.0] 11 [1.0] 21 [1.3] 17 [1.2]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 2
NTP Experiment-Test: 96021-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 10/09/03
Route: GAVAGE TOXIC EQUIVALENCY FACTOR EVALUATION (PCB 153) Time: 10:00:49
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 UG/KG 10 UG/KG 100 300 1000 3000
UG/KG UG/KG UG/KG UG/KG
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Fatty Change, Focal 4 [1.0] 3 [1.0] 5 [1.2] 4 [1.0] 1 [1.0]
Hematopoietic Cell Proliferation 20 [1.1] 22 [1.1] 13 [1.1] 18 [1.3] 16 [1.0] 14 [1.2]
Hepatodiaphragmatic Nodule 1 1
Hyperplasia, Nodular 1
Inflammation 44 [1.2] 39 [1.2] 44 [1.1] 47 [1.1] 48 [1.1] 45 [1.3]
Mixed Cell Focus 8 3 7 6 5 3
Mixed Cell Focus, Multiple 21 16 22 19 19 12
Necrosis 7 [2.4] 7 [2.0] 7 [2.1] 5 [1.6] 12 [2.1] 10 [2.3]
Pigmentation 1 [1.0] 1 [1.0] 2 [1.5] 5 [1.6] 5 [1.2] 9 [1.0]
Bile Duct, Cyst 3 [2.7] 2 [2.0] 2 [2.5] 3 [2.0] 5 [2.6] 2 [2.5]
Bile Duct, Fibrosis 2 [1.0] 1 [1.0] 2 [1.5] 2 [1.0] 2 [1.0] 3 [1.0]
Bile Duct, Hyperplasia 5 [1.8] 3 [2.0] 2 [1.0] 14 [1.6] 10 [1.6] 17 [1.6]
Centrilobular, Degeneration 2 [2.0] 10 [2.4] 4 [2.3] 2 [2.0] 2 [2.0] 5 [2.0]
Hepatocyte, Hypertrophy 5 [1.2] 5 [1.4] 24 [1.4] 39 [2.0] 41 [2.3]
Oval Cell, Hyperplasia 1 [1.0] 4 [1.3]
Serosa, Fibrosis 1 [3.0]
Serosa, Inflammation 2 [3.0]
Mesentery (1) (1)
Fat, Inflammation, Chronic Active 1 [3.0]
Oral Mucosa (21) (12) (16) (12) (16) (25)
Gingival, Hyperplasia, Squamous 21 [1.0] 10 [1.7] 16 [1.1] 11 [1.1] 16 [1.4] 25 [1.1]
Pancreas (53) (54) (53) (53) (53) (51)
Cyst 1 [2.0]
Degeneration 1 [2.0]
Inflammation, Chronic Active 2 [2.0] 1 [1.0] 1 [2.0] 2 [1.0]
Acinus, Atrophy 1 [1.0] 1 [2.0] 1 [2.0] 2 [1.5]
Acinus, Hyperplasia 3 [2.7]
Acinus, Vacuolization Cytoplasmic 1 [1.0] 1 [1.0] 2 [1.5]
Salivary Glands (51) (52) (53) (52) (53) (51)
Ectopic Tissue 1
Stomach, Forestomach (53) (54) (53) (53) (53) (51)
Hyperkeratosis 1 [2.0] 1 [2.0] 2 [2.0]
Hyperplasia, Squamous 3 [2.0] 4 [1.8] 2 [2.0] 6 [1.7] 4 [1.8] 4 [2.5]
Inflammation 3 [2.0] 3 [1.7] 2 [3.0]
Mineralization 1 [1.0] 2 [1.5] 2 [2.0]
Ulcer 2 [3.0] 3 [2.0] 1 [2.0]
Serosa, Inflammation, Chronic Active 1 [3.0]
Stomach, Glandular (53) (54) (53) (53) (53) (51)
Erosion 1 [2.0] 1 [2.0] 2 [2.0]
Inflammation 2 [2.0]
Mineralization 5 [1.8] 8 [1.3] 8 [1.3] 10 [1.5] 10 [1.5] 2 [1.5]
Tooth (34) (13) (19) (22) (23) (35)
Degeneration 1 [3.0]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 3
NTP Experiment-Test: 96021-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 10/09/03
Route: GAVAGE TOXIC EQUIVALENCY FACTOR EVALUATION (PCB 153) Time: 10:00:49
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 UG/KG 10 UG/KG 100 300 1000 3000
UG/KG UG/KG UG/KG UG/KG
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Peridontal Tissue, Inflammation 33 [1.2] 13 [1.4] 19 [1.1] 21 [1.2] 23 [1.4] 35 [1.3]
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Blood Vessel (52) (54) (53) (53) (53) (51)
Aorta, Mineralization 2 [2.0] 1 [2.0] 1 [2.0] 1 [2.0]
Heart (52) (54) (53) (53) (53) (51)
Cardiomyopathy 22 [1.1] 18 [1.2] 19 [1.0] 19 [1.2] 23 [1.1] 24 [1.1]
Inflammation 2 [3.0] 1 [2.0] 1 [1.0]
Mineralization 1 [2.0] 1 [1.0]
Necrosis 1 [3.0]
Thrombosis 2 [3.0]
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (53) (54) (53) (53) (53) (51)
Angiectasis 21 [1.9] 23 [1.7] 34 [1.8] 25 [1.6] 29 [1.6] 21 [1.9]
Atrophy 1 [2.0] 2 [2.0]
Degeneration, Cystic 9 [2.1] 12 [2.2] 15 [2.3] 13 [2.2] 12 [2.0] 13 [1.8]
Hematopoietic Cell Proliferation 1 [1.0] 1 [1.0] 3 [1.3]
Hyperplasia 18 [2.4] 24 [2.4] 27 [2.6] 27 [2.4] 28 [2.4] 11 [2.5]
Hypertrophy 48 [2.1] 35 [1.9] 45 [1.8] 35 [1.9] 42 [1.9] 41 [2.0]
Inflammation 1 [1.0] 1 [1.0]
Mineralization 2 [2.0] 1 [2.0]
Necrosis 1 [3.0] 2 [2.5] 1 [2.0] 2 [3.5] 3 [2.7] 3 [2.0]
Vacuolization Cytoplasmic 10 [1.3] 8 [1.5] 14 [1.5] 16 [1.8] 12 [1.5] 14 [1.6]
Adrenal Medulla (53) (54) (53) (53) (53) (51)
Angiectasis 1 [2.0] 1 [2.0]
Hyperplasia 18 [2.1] 14 [2.1] 19 [1.9] 14 [2.3] 20 [2.1] 12 [1.9]
Islets, Pancreatic (53) (54) (53) (53) (53) (51)
Hyperplasia 1 [2.0] 1 [2.0] 1 [2.0]
Parathyroid Gland (49) (46) (50) (47) (46) (48)
Angiectasis 1 [1.0]
Cyst 1 [2.0]
Fibrosis 1 [3.0]
Hyperplasia 2 [1.5] 1 [2.0] 1 [2.0]
Pituitary Gland (53) (54) (53) (53) (53) (50)
Angiectasis 15 [2.0] 16 [2.5] 20 [2.5] 26 [2.2] 28 [2.4] 14 [2.3]
Atypia Cellular 1 [2.0]
Cyst 1 [2.0] 1 [2.0]
Cytoplasmic Alteration 2 [1.5] 1 [2.0] 1 [2.0]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 4
NTP Experiment-Test: 96021-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 10/09/03
Route: GAVAGE TOXIC EQUIVALENCY FACTOR EVALUATION (PCB 153) Time: 10:00:49
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 UG/KG 10 UG/KG 100 300 1000 3000
UG/KG UG/KG UG/KG UG/KG
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - CONT
Vacuolization Cytoplasmic 1 [1.0]
Pars Distalis, Hyperplasia 23 [2.4] 18 [2.2] 22 [2.4] 16 [2.4] 23 [2.3] 25 [2.2]
Thyroid Gland (51) (52) (53) (53) (53) (51)
Angiectasis 1 [2.0] 1 [2.0]
C-Cell, Hyperplasia 19 [1.9] 17 [2.1] 23 [2.0] 17 [1.6] 19 [1.9] 16 [1.9]
Follicular Cell, Hyperplasia 1 [2.0] 2 [2.0] 2 [1.5]
Follicular Cell, Hypertrophy 5 [2.0] 9 [1.7] 9 [1.9] 12 [1.7] 10 [2.1] 17 [1.8]
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (53) (51) (52) (53) (51) (50)
Atrophy 1 [2.0]
Inflammation 52 [1.6] 45 [1.9] 41 [1.8] 48 [1.6] 48 [1.6] 46 [1.4]
Inflammation, Chronic Active 1 [4.0]
Duct, Cyst 49 [2.3] 40 [2.5] 36 [2.4] 43 [2.4] 45 [2.3] 41 [2.3]
Ovary (53) (53) (53) (53) (53) (50)
Atrophy 47 [4.0] 43 [4.0] 42 [4.0] 38 [4.0] 44 [3.9] 39 [3.9]
Cyst 14 [2.2] 7 [2.3] 17 [2.2] 17 [2.2] 16 [2.3] 17 [2.2]
Inflammation, Chronic Active 2 [3.5] 1 [2.0] 5 [3.0] 7 [3.6]
Necrosis 1 [2.0]
Interstitial Cell, Hyperplasia 1 [2.0] 1 [3.0]
Oviduct (50) (38) (44) (35) (39) (45)
Cyst 1 [2.0] 2 [3.0] 1 [2.0] 1 [3.0]
Dilatation 1 [3.0] 1 [4.0]
Inflammation, Chronic Active 1 [3.0] 2 [2.5] 1 [3.0] 5 [3.2] 7 [3.3]
Uterus (53) (54) (53) (53) (53) (50)
Adenomyosis 2 [3.5] 1 [2.0] 1 [2.0] 1 [3.0]
Angiectasis 1 [3.0] 1 [3.0]
Congestion 1 [1.0]
Cyst 1 [3.0] 1 [3.0]
Hemorrhage 2 [3.0]
Inflammation, Chronic Active 2 [3.0] 1 [3.0] 5 [2.4] 4 [2.8] 2 [3.0] 8 [3.0]
Inflammation, Suppurative 5 [1.6] 6 [1.8] 6 [1.8] 2 [1.0] 16 [2.0] 8 [1.6]
Metaplasia, Squamous 23 [2.3] 29 [2.1] 27 [2.5] 17 [2.3] 27 [2.7] 32 [2.6]
Thrombosis 1 [3.0] 2 [3.0]
Ulcer 1 [2.0]
Cervix, Hyperplasia, Stromal 1 [3.0] 2 [3.0]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 5
NTP Experiment-Test: 96021-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 10/09/03
Route: GAVAGE TOXIC EQUIVALENCY FACTOR EVALUATION (PCB 153) Time: 10:00:49
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 UG/KG 10 UG/KG 100 300 1000 3000
UG/KG UG/KG UG/KG UG/KG
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - CONT
Cervix, Inflammation, Suppurative 1 [3.0]
Endometrium, Hyperplasia, Cystic 37 [2.4] 29 [2.1] 32 [2.4] 28 [2.3] 25 [2.2] 21 [2.1]
Endometrium, Hyperplasia, Stromal 1 [3.0]
Vagina (1) (3) (2) (1) (1) (3)
Inflammation 1 [1.0]
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (53) (54) (53) (53) (53) (51)
Hyperplasia 34 [2.9] 41 [3.3] 40 [3.0] 38 [3.1] 42 [3.2] 46 [2.9]
Lymph Node (3) (3) (3) (2) (5) (6)
Hemorrhage 1 [2.0]
Hyperplasia, Lymphoid 1 [3.0]
Hyperplasia, Plasma Cell 1 [3.0] 1 [3.0]
Iliac, Ectasia 1 [2.0]
Iliac, Hyperplasia, Plasma Cell 1 [3.0]
Lumbar, Ectasia 1 [3.0] 2 [3.0] 2 [2.5]
Lumbar, Hemorrhage 1 [2.0] 1 [2.0]
Lumbar, Hyperplasia, Histiocytic 1 [2.0]
Lumbar, Hyperplasia, Plasma Cell 1 [3.0] 2 [2.0]
Mediastinal, Congestion 3 [2.0]
Mediastinal, Ectasia 2 [2.0]
Mediastinal, Hyperplasia, Histiocytic 1 [2.0]
Mediastinal, Hyperplasia, Lymphoid 1 [2.0] 1 [2.0]
Mediastinal, Hyperplasia, Plasma Cell 1 [3.0] 1 [2.0]
Renal, Ectasia 2 [3.5]
Renal, Hyperplasia, Plasma Cell 1 [2.0]
Renal, Inflammation, Chronic Active 1 [4.0]
Lymph Node, Mandibular (51) (52) (53) (51) (53) (51)
Congestion 1 [2.0]
Ectasia 1 [2.0] 1 [2.0] 1 [3.0]
Hemorrhage 1 [2.0]
Hyperplasia, Lymphoid 1 [2.0] 1 [2.0] 2 [2.5] 1 [2.0] 3 [2.3] 1 [2.0]
Hyperplasia, Plasma Cell 37 [2.3] 36 [2.2] 30 [2.3] 33 [2.4] 37 [2.4] 38 [2.3]
Inflammation 1 [3.0]
Lymph Node, Mesenteric (52) (54) (53) (53) (53) (51)
Ectasia 1 [1.0]
Hemorrhage 1 [2.0]
Hyperplasia, Plasma Cell 1 [3.0]
Inflammation, Chronic Active 1 [4.0]
Spleen (53) (54) (53) (53) (53) (51)
Hematopoietic Cell Proliferation 46 [1.7] 48 [2.3] 52 [2.2] 48 [1.9] 46 [1.8] 47 [1.7]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 6
NTP Experiment-Test: 96021-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 10/09/03
Route: GAVAGE TOXIC EQUIVALENCY FACTOR EVALUATION (PCB 153) Time: 10:00:49
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 UG/KG 10 UG/KG 100 300 1000 3000
UG/KG UG/KG UG/KG UG/KG
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - CONT
Hemorrhage 1 [3.0]
Infarct 1 [3.0]
Necrosis 1 [2.0] 1 [2.0] 1 [3.0]
Pigmentation 47 [1.5] 42 [1.5] 47 [1.6] 49 [1.4] 49 [1.5] 46 [1.4]
Lymphoid Follicle, Atrophy 1 [2.0] 6 [2.3] 2 [2.0] 3 [2.7] 3 [2.0] 3 [2.7]
Red Pulp, Atrophy 2 [2.5]
Thymus (48) (53) (52) (53) (53) (47)
Atrophy 38 [2.6] 38 [2.7] 37 [2.7] 35 [2.6] 41 [2.7] 30 [2.6]
Cyst 1 [3.0] 1 [2.0]
Hemorrhage 3 [2.3]
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (53) (54) (53) (53) (53) (51)
Cyst 2 [3.0] 1 [3.0] 2 [2.5] 1 [2.0] 3 [2.7]
Hyperplasia 22 [1.5] 23 [1.4] 32 [1.2] 27 [1.4] 32 [1.3] 22 [1.4]
Inflammation, Chronic Active 1 [3.0]
Inflammation, Granulomatous 2 [2.0] 2 [2.0] 3 [1.7] 1 [2.0]
Skin (53) (54) (53) (53) (53) (51)
Cyst 1 [2.0]
Cyst Epithelial Inclusion 1 1
Inflammation 1 [2.0]
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
None
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (53) (54) (53) (53) (53) (51)
Hemorrhage 1 [3.0] 1 [2.0] 1 [2.0] 2 [3.0]
Hydrocephalus 2 [2.0] 1 [1.0]
Hyperplasia, Histiocytic 1 [3.0]
Mineralization 1 [2.0]
Necrosis 1 [3.0] 1 [2.0]
Vacuolization Cytoplasmic 1 [2.0]
Glial Cell, Hyperplasia 1 [3.0]
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 7
NTP Experiment-Test: 96021-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 10/09/03
Route: GAVAGE TOXIC EQUIVALENCY FACTOR EVALUATION (PCB 153) Time: 10:00:49
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 UG/KG 10 UG/KG 100 300 1000 3000
UG/KG UG/KG UG/KG UG/KG
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (52) (54) (53) (53) (53) (51)
Congestion 1 [2.0]
Hemorrhage 1 [2.0] 1 [1.0]
Infiltration Cellular, Histiocyte 45 [1.6] 40 [1.6] 40 [1.8] 40 [1.4] 27 [1.4] 28 [1.3]
Inflammation 6 [2.2] 7 [1.9] 2 [2.0] 6 [2.2] 7 [1.7] 9 [1.7]
Metaplasia, Squamous 1 [1.0] 1 [2.0] 1 [2.0]
Mineralization 1 [3.0] 1 [3.0]
Alveolar Epithelium, Hyperplasia 20 [1.1] 21 [1.4] 16 [1.3] 11 [1.2] 9 [1.1] 6 [1.0]
Mediastinum, Hemorrhage 1 [3.0]
Serosa, Inflammation, Chronic Active 1 [3.0]
Nose (53) (54) (53) (53) (53) (51)
Cyst 1 [3.0]
Inflammation 1 [1.0] 6 [2.0] 3 [2.0] 6 [1.5] 6 [1.8] 3 [2.0]
Goblet Cell, Hyperplasia 2 [2.5] 1 [2.0] 2 [2.0]
Nasolacrimal Duct, Inflammation 2 [3.0] 2 [2.5]
Respiratory Epithelium, Hyperplasia 2 [2.0] 1 [2.0]
Respiratory Epithelium, Mineralization 1 [2.0]
Septum, Inflammation 4 [1.5] 3 [2.0] 5 [1.8] 3 [1.0] 7 [1.4] 6 [1.5]
Squamous Epithelium, Hyperplasia 1 [2.0]
Turbinate, Inflammation 8 [1.1] 3 [1.7] 5 [1.4] 9 [1.4] 10 [1.7] 10 [1.5]
Trachea (52) (54) (53) (53) (53) (51)
Inflammation 1 [2.0]
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (53) (54) (53) (53) (52) (51)
Degeneration 1 [3.0]
Anterior Chamber, Exudate 1 [2.0]
Lens, Degeneration 1 [1.0]
Retina, Atrophy 2 [1.5] 1 [1.0] 1 [1.0]
Harderian Gland (53) (54) (53) (53) (53) (49)
Atrophy 1 [1.0]
Inflammation 20 [1.0] 9 [1.1] 13 [1.1] 16 [1.1] 16 [1.1] 16 [1.2]
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (53) (54) (53) (53) (53) (51)
Accumulation, Hyaline Droplet 3 [2.0] 1 [3.0] 1 [1.0]
Calculus Micro Observation Only 3 5 4 7 5 1
Casts Protein 3 [1.0] 2 [1.5] 2 [1.0] 1 [2.0] 1 [2.0]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 8
NTP Experiment-Test: 96021-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 10/09/03
Route: GAVAGE TOXIC EQUIVALENCY FACTOR EVALUATION (PCB 153) Time: 10:00:49
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 UG/KG 10 UG/KG 100 300 1000 3000
UG/KG UG/KG UG/KG UG/KG
____________________________________________________________________________________________________________________________________
URINARY SYSTEM - CONT
Cyst 1 [2.0] 1 [2.0]
Degeneration 1 [2.0]
Hydronephrosis 1 [3.0] 1 [3.0]
Infarct 1 [3.0] 1 [3.0] 2 [2.5]
Inflammation, Chronic Active 2 [1.0] 3 [1.7] 1 [1.0]
Inflammation, Suppurative 1 [1.0] 2 [2.0] 3 [1.0] 2 [1.0] 2 [1.0] 3 [2.0]
Mineralization 40 [1.1] 42 [1.1] 41 [1.0] 39 [1.1] 40 [1.1] 41 [1.0]
Necrosis 1 [3.0]
Nephropathy 34 [1.1] 23 [1.1] 24 [1.0] 33 [1.1] 28 [1.2] 34 [1.1]
Pelvis, Dilatation 2 [2.5]
Pelvis, Inflammation 1 [2.0] 4 [2.0] 2 [2.5] 4 [2.3] 5 [1.8] 4 [2.0]
Renal Tubule, Degeneration 1 [3.0] 1 [3.0]
Renal Tubule, Hyperplasia 1 [2.0]
Transitional Epithelium, Hyperplasia 1 [2.0] 5 [1.8] 2 [2.5] 4 [2.0] 6 [1.8] 4 [2.3]
Ureter (1)
Cyst 1 [3.0]
Urinary Bladder (53) (53) (53) (53) (53) (50)
Calculus Micro Observation Only 1
Inflammation 8 [1.1] 11 [1.6] 6 [1.7] 8 [2.0] 13 [1.2] 9 [1.9]
Transitional Epithelium, Hyperplasia 3 [2.3] 2 [2.5] 3 [2.0] 2 [2.0] 3 [2.3]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 9
NTP Experiment-Test: 96021-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 10/09/03
Route: GAVAGE TOXIC EQUIVALENCY FACTOR EVALUATION (PCB 153) Time: 10:00:49
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 3000 UG/
KG STOP
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 50
Early Deaths
Natural Death 14
Moribund Sacrifice 16
Survivors
Terminal Sacrifice 20
Animals Examined Microscopically 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (49)
Muscularis, Inflammation 3 [1.3]
Intestine Large, Rectum (50)
Parasite Metazoan 3
Intestine Large, Cecum (48)
Inflammation 1 [3.0]
Ulcer 1 [3.0]
Liver (50)
Angiectasis 8 [1.6]
Basophilic Focus 8
Basophilic Focus, Multiple 2
Clear Cell Focus 1
Degeneration, Cystic 1 [2.0]
Eosinophilic Focus 4
Eosinophilic Focus, Multiple 10
Fatty Change, Diffuse 15 [1.1]
Fatty Change, Focal 6 [1.2]
Hematopoietic Cell Proliferation 17 [1.2]
Hepatodiaphragmatic Nodule 2
Hyperplasia, Histiocytic 1 [2.0]
Hyperplasia, Nodular 1
Inflammation 44 [1.1]
Mixed Cell Focus 7
Mixed Cell Focus, Multiple 13
Necrosis 9 [2.7]
Pigmentation 3 [1.3]
Bile Duct, Cyst 3 [2.0]
Bile Duct, Fibrosis 5 [1.2]
Bile Duct, Hyperplasia 12 [1.7]
Centrilobular, Degeneration 5 [2.2]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 10
NTP Experiment-Test: 96021-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 10/09/03
Route: GAVAGE TOXIC EQUIVALENCY FACTOR EVALUATION (PCB 153) Time: 10:00:49
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 3000 UG/
KG STOP
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Hepatocyte, Hypertrophy 32 [1.8]
Oval Cell, Hyperplasia 2 [1.0]
Oral Mucosa (15)
Gingival, Hyperplasia, Squamous 15 [1.1]
Pancreas (50)
Inflammation, Chronic Active 2 [1.0]
Acinus, Atrophy 3 [2.0]
Acinus, Hyperplasia 2 [2.0]
Acinus, Vacuolization Cytoplasmic 1 [2.0]
Salivary Glands (48)
Inflammation, Chronic Active 1 [2.0]
Stomach, Forestomach (50)
Hyperkeratosis 2 [2.0]
Hyperplasia, Squamous 5 [2.0]
Inflammation 4 [1.5]
Mineralization 3 [1.7]
Stomach, Glandular (50)
Inflammation 1 [3.0]
Mineralization 3 [1.3]
Ulcer 1 [3.0]
Serosa, Inflammation 1 [2.0]
Tooth (27)
Peridontal Tissue, Inflammation 27 [1.4]
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50)
Cardiomyopathy 15 [1.1]
Epicardium, Inflammation 1 [1.0]
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50)
Angiectasis 20 [1.7]
Degeneration, Cystic 7 [1.7]
Hematopoietic Cell Proliferation 2 [1.5]
Hyperplasia 18 [2.3]
Hypertrophy 35 [1.8]
Necrosis 1 [2.0]
Vacuolization Cytoplasmic 12 [1.1]
Adrenal Medulla (50)
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 11
NTP Experiment-Test: 96021-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 10/09/03
Route: GAVAGE TOXIC EQUIVALENCY FACTOR EVALUATION (PCB 153) Time: 10:00:49
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 3000 UG/
KG STOP
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - CONT
Angiectasis 1 [2.0]
Hyperplasia 19 [2.2]
Parathyroid Gland (45)
Hyperplasia 1 [2.0]
Pituitary Gland (50)
Angiectasis 24 [2.3]
Pars Distalis, Hyperplasia 18 [2.4]
Rathke's Cleft, Pars Nervosa, Cyst 1 [2.0]
Thyroid Gland (49)
C-Cell, Hyperplasia 13 [1.9]
Follicular Cell, Hypertrophy 12 [1.8]
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (48)
Inflammation 44 [1.5]
Duct, Cyst 41 [2.3]
Ovary (49)
Atrophy 41 [3.9]
Cyst 16 [2.4]
Oviduct (46)
Dilatation 1 [3.0]
Inflammation, Chronic Active 2 [3.0]
Uterus (49)
Cyst 1 [4.0]
Inflammation, Chronic Active 1 [3.0]
Inflammation, Suppurative 9 [2.2]
Metaplasia, Squamous 24 [2.7]
Cervix, Cyst 1 [3.0]
Cervix, Hyperplasia, Stromal 2 [3.0]
Endometrium, Hyperplasia, Cystic 23 [1.8]
Vagina (1)
Inflammation, Chronic Active 1 [3.0]
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 12
NTP Experiment-Test: 96021-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 10/09/03
Route: GAVAGE TOXIC EQUIVALENCY FACTOR EVALUATION (PCB 153) Time: 10:00:49
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 3000 UG/
KG STOP
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - CONT
Bone Marrow (50)
Hyperplasia 40 [3.1]
Lymph Node (1)
Mediastinal, Hemorrhage 1 [2.0]
Lymph Node, Mandibular (48)
Ectasia 1 [2.0]
Hyperplasia, Lymphoid 1 [3.0]
Hyperplasia, Plasma Cell 37 [2.5]
Inflammation 1 [3.0]
Spleen (50)
Accessory Spleen 1
Congestion 1 [3.0]
Hematopoietic Cell Proliferation 44 [1.9]
Hemorrhage 1 [2.0]
Pigmentation 50 [1.3]
Lymphoid Follicle, Atrophy 4 [2.3]
Thymus (49)
Atrophy 29 [2.4]
Hemorrhage 1 [3.0]
Inflammation 1 [3.0]
Necrosis, Lymphoid 1 [2.0]
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (50)
Cyst 3 [2.3]
Cyst, Multiple 1 [3.0]
Hyperplasia 27 [1.5]
Inflammation, Granulomatous 2 [1.5]
Skin (50)
Ulcer 1 [4.0]
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
None
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 13
NTP Experiment-Test: 96021-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 10/09/03
Route: GAVAGE TOXIC EQUIVALENCY FACTOR EVALUATION (PCB 153) Time: 10:00:49
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 3000 UG/
KG STOP
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50)
Hemorrhage 1 [2.0]
Infiltration Cellular, Histiocyte 37 [1.3]
Inflammation 9 [1.8]
Alveolar Epithelium, Hyperplasia 4 [1.3]
Nose (50)
Inflammation 2 [1.5]
Septum, Inflammation 4 [1.3]
Turbinate, Inflammation 5 [1.2]
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (50)
Retina, Atrophy 2 [2.0]
Harderian Gland (50)
Inflammation 15 [1.2]
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50)
Casts Protein 4 [1.0]
Cyst 1 [2.0]
Fibrosis 1 [1.0]
Inflammation, Chronic Active 3 [2.7]
Inflammation, Suppurative 2 [2.0]
Mineralization 38 [1.0]
Nephropathy 22 [1.2]
Pelvis, Inflammation 3 [1.3]
Transitional Epithelium, Hyperplasia 4 [1.5]
Urinary Bladder (49)
Inflammation 10 [1.7]
Transitional Epithelium, Hyperplasia 3 [2.0]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 14
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------